S F Schmitz
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
01.01.2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
01.01.2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
Pichert G, Stahel R, Schmitter D, Stupp R, Betticher D, Cogliatti S, Cerny T, Hess U, Schmitz S, Ghielmini M. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. Clinical lymphoma 2001; 1:293-7.
01.03.2001Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
01.03.2001Clinical lymphoma 2001; 1:293-7
Pichert G, Stahel R A, Schmitter D, Stupp R, Betticher D, Cogliatti S B, Cerny Thomas, Hess U, Schmitz S F, Ghielmini M
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D, Pichert G, Bürki K, Schmitz S, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 1:123-6.
01.01.2000The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
01.01.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 1:123-6
Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D C, Pichert G, Bürki K, Schmitz S F, Cerny Thomas
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
Cerny T, Brunner J, Sessa C, Honegger P, Schmitz S, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94.
01.09.1999Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
01.09.1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94
Cerny Thomas, Brunner J, Sessa C, Honegger P, Schmitz S F, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A V
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.
01.06.1999Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
01.06.1999Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S F, Thürlimann Beat, Hürny C
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.
01.06.1999Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
01.06.1999European journal of cancer (Oxford, England : 1990) 1999; 35:913-20
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Thürlimann Beat, Schmitz S F, Castiglione-Gertsch M, Hürny C